Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Gongwin Biopharm Holdings Co's Revenue for the
three
months ended in Mar. 2026 was NT$9.47 Mil. Gongwin Biopharm Holdings Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$10.42 Mil.
Hence, Gongwin Biopharm Holdings Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.91.
Gongwin Biopharm Holdings Co (ROCO:6617) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Gongwin Biopharm Holdings Co Receivables Turnover Related Terms
Gongwin Biopharm Holdings Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co Receivables Turnover Chart
ROCO:6617 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Gongwin Biopharm Holdings Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gongwin Biopharm Holdings Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gongwin Biopharm Holdings Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Gongwin Biopharm Holdings Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gongwin Biopharm Holdings Co (ROCO:6617) has a Receivables Turnover of 0.91 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gongwin Biopharm Holdings Co and its competitors. According to the industry distribution chart, Gongwin Biopharm Holdings Co ranks #635 out of 845 companies in the Biotechnology industry, placing it in the top 75.1%.
Is Gongwin Biopharm Holdings Co's Receivables Turnover too high?
Gongwin Biopharm Holdings Co's current Receivables Turnover is 0.91. The Biotechnology industry median Receivables Turnover is 5.22. Gongwin Biopharm Holdings Co's value of 0.91 is 82.6% below this industry median. Based on the distribution chart, Gongwin Biopharm Holdings Co ranks #635 out of 845 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gongwin Biopharm Holdings Co ranks #635 out of 845 companies for Receivables Turnover. This places Gongwin Biopharm Holdings Co in the lower half of its industry. The industry median Receivables Turnover is 5.22. Gongwin Biopharm Holdings Co's value of 0.91 is 82.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.22, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gongwin Biopharm Holdings Co's current Receivables Turnover of 0.91 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Gongwin Biopharm Holdings Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gongwin Biopharm Holdings Co's current Receivables Turnover is 0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Gongwin Biopharm Holdings Co (ROCO:6617) has a current Receivables Turnover of 0.91. The current Receivables Turnover is 0.91 and 82.6% below the Biotechnology industry median of 5.22. Gongwin Biopharm Holdings Co's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current Receivables Turnover is 0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
47GF Score
Get the complete analysis for ROCO:6617
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6617 has been successfully added to your 
